A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout

Lisa K Stamp1, 2, Peter T Chapman2, Murray L Barclay1, Anne Horne3, Christopher Frampton1, Paul Tan3, Jill Drake1, Nicola Dalbeth3

Abstract

Objectives To determine the efficacy and safety of allopurinol dose escalation using a treat-to-target serum urate (SU) approach.

Methods A randomised, controlled, parallel-group, comparative clinical trial was undertaken. People with gout receiving at least creatinine clearance (CrCL)-based allopurinol dose for ≥1 month and SU ≥6 mg/dL were recruited. Participants were randomised to continue current dose (control) or allopurinol dose escalation for 12 months. In the dose escalation group, allopurinol was increased monthly until SU was <6 mg/dL. The primary endpoints were reduction in SU and adverse events (AEs).

Results 183 participants (93 control, 90 dose escalation) were recruited. At baseline, mean (SD) urate was 7.15 (1.6) mg/dL and allopurinol dose 269 mg/day. 52% had CrCL<60 mL/min. Mean changes in SU at the final visit were −0.34 mg/dL in the control group and −1.5 mg/dL in the dose escalation group (p<0.001) with a mean difference of 1.2 mg/dL (95% CI 0.67 to 1.5, p<0.001). At month 12, 32% of controls and 69% in the dose escalation had SU <6 mg/dL. There were 43 serious AEs in 25 controls and 35 events in 22 dose escalation participants. Only one was considered probably related to allopurinol. Five control and five dose escalation participants died; none was considered allopurinol related. Mild elevations in LFTs were common in both groups, a few moderate increases in gamma glutamyl transferase (GGT) were noted. There was no difference in renal function changes between randomised groups.

Conclusions Higher than CrCL-based doses of allopurinol can effectively lower SU to treatment target in most people with gout. Allopurinol dose escalation is well tolerated.
Trial registration number: ANZCTR12611000845932; Results.
http://dx.doi.org/10.1136/annrheumdis-2016-210872

Statistics from Altmetric.com

Picked up by 2 news outlets
Tweeted by 7
6 readers on Mendeley

See more details

View Full Text

Footnotes

Handling editor Tore K Kvien

Contributors: LKS and ND: literature search, study design, data collection, data analysis, data interpretation and manuscript preparation. PTC and JD: study design, data collection, data analysis, data interpretation and manuscript preparation. MLB and CF: study design, data analysis, data interpretation and manuscript preparation. AH and PT: data collection, data analysis, data interpretation and manuscript preparation.

Funding: This study was funded by the Health Research Council of New Zealand (11/203).

Competing interests: LKS reports grants from Health Research Council of New Zealand, during the conduct of the study; grants from Ardea Biosciences, grants from Health Research Council of New Zealand, outside the submitted work; AH reports grants from Health Research Council of New Zealand, during the conduct of the study; ND reports grants from Health Research Council of New Zealand, during the conduct of the study; grants from Health Research Council of New Zealand, grants and personal fees from AstraZeneca, grants and personal fees from Ardea Biosciences, personal fees from Takeda, personal fees from Teijin, personal fees from Menarini, grants from Fonterra, personal fees from Pfizer, personal fees from Crealta, personal fees from Cymabay, outside the submitted work.

Patient consent: Obtained.

Ethics approval: MultiRegional Ethics Committee of New Zealand.

Provenance and peer review: Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

http://ard.bmj.com/content/early/2017/03/17/annrheumdis-2016-210872

2017/04/09
Recruiter: Milton Keynes University Hospital NHS Foundation Trust
Apply for this job

Consultant Rheumatologist (two posts)
Milton Keynes, Buckinghamshire | £76,761 to £103,490
Applications are invited for two Consultant posts in Rheumatology with Milton Keynes University Hospital NHS Foundation Trust
Recruiter: Milton Keynes University Hospital NHS Foundation Trust
Apply for this job

Specialist Registrar ST3+ Level in Rheumatology and GIM
Hackney, London | £32,464 to £49,809
There is the opportunity to gain experience in performing musculoskeletal ultrasound and to be involved in several research and audit projects
Recruiter: Homerton University Hospital NHS Foundation Trust
Apply for this job

Consultant Rheumatologist - 10 PAs
Preston, Lancashire
High quality care in the right place, at the right time, every time. Applications are invited for the F/T post of Consultant Rheumatologist at the...
Recruiter: Lancashire Care NHS Foundation Trust
Apply for this job

Consultant Rheumatologist
Hereford, County of Herefordshire | £76,001 - £102,465
We recommend

Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)
Thomas Bardin et al., Ann Rheum Dis, 2016

A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
M K Reinders et al., Ann Rheum Dis, 2008

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol
Chris Storgard et al., Ann Rheum Dis, 2016

Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?
Jasvinder A Singh, Ann Rheum Dis, 2016

Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
M K Reinders et al., Ann Rheum Dis, 2008
A randomised controlled trial of the efficacy and safety of allopurinol dose escalation t...